Stemgent, a provider of consumable research materials for stem cell scientists, has raised $5.6 million of a planned $10.1 million round of equity funding, according to an SEC filing. The funding includes the conversion of promissory notes. The company, which has offices in Cambridge, MA, and San Diego, previously raised $14 million in March 2009 from HealthCare Ventures and Morgenthaler Ventures.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
